G Medical Innovations (GMVDF) 6-K 15 Sep 21 2021 Q2 Report of Foreign Private Issuer Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	G MEDICAL INNOVATIONS HOLDINGS LTD.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001760764
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity File Number	001-39674

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Statements of Financial Position - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	[1]
Assets
Cash and cash equivalents	$ 13,380	$ 278
Restricted deposit	629	630
Inventories	46	90
Trade receivables, net	672	717
Other accounts receivable	718	1,420
Total current assets	15,445	3,135
Other accounts receivable	233
Property, plant and equipment, net	1,542	2,315
Total non-current assets	1,775	2,315
Total assets	17,220	5,450
Liabilities and Shareholder’s
Short term loan and current portion of long-term loans	426	1,635
Trade payables	3,302	3,105	[2]
Loan from controlling shareholder	642	272
Convertible debenture	1,331	194
Derivative liabilities – warrants	343	359
Short term portion of lease liability	127	255
Financial liability
Other accounts payable	3,993	2,081	[2]
Total current liabilities	10,164	7,901
Long term lease liability	13	50
Long term loans	393	448
Total non-current liabilities	406	498
Shareholder’s Equity (Deficit)
Ordinary shares	1,212	819
Other reserve	1,500	1,500
Translation reserve	2	2
Additional paid in capital	81,234	67,257
Accumulated deficit	(80,570)	(75,876)
G Medical Innovations Holdings Ltd. shareholders’ equity (deficit)	3,378	(6,298)
Non-controlling interest	3,272	3,349
Total shareholders’ equity (deficit)	6,650	(2,949)
Total Liabilities and Shareholders’ Equity (Deficit)	$ 17,220	$ 5,450
[1]	The December 31, 2020 balances were derived from the Company’s audited annual financial statements.
[2]	Reclassification

Unaudited Interim Condensed C_2

Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2021	Jun. 30, 2020
Revenue:
Services		$ 2,875	$ 1,981
Products		50	29
Total revenue		2,925	2,010
Cost of revenue:
Cost of services		1,726	2,214
Cost of sales of products		58	320
Total cost of revenue		1,784	2,534
Gross profit (loss)		1,141	(524)
Operating expenses:
Research and development expenses		619	699
Selling, general and administrative expenses		4,532	3,375
Expected credit loss		263	36
Operating loss		(4,273)	(4,634)
Finance income		447	205
Finance expenses		950	561
Financial expenses, net		503	356
Loss before tax		(4,776)	(4,990)
Income tax benefit		5	9
Loss for the period		(4,771)	(4,981)
Other comprehensive income, net of tax:
Exchange gains arising on translation of foreign operations
Other comprehensive income
Total comprehensive loss for the period		(4,771)	(4,981)
Loss for the period attributed to:
Non-controlling interests		(77)	(81)
The Company’s shareholders		(4,694)	(4,900)
Total loss		(4,771)	(4,981)
Total comprehensive loss for the period attributed to:
Non-controlling interests		(77)	(81)
The Company’s shareholders		(4,694)	(4,900)
Total comprehensive loss		$ (4,771)	$ (4,981)
Basic and diluted loss per share attributable to the Company’s shareholders in USD (in Dollars per share)	[1]		$ (0.84)
[1]	After giving effect to the reverse stock split (see also Note 4).

Unaudited Interim Condensed C_3

Unaudited Interim Condensed Consolidated Statements of Changes in Equity (Deficit) - USD ($) $ in Thousands	Share capital	Other reserve	Translation reserve	Additional paid in capital	Accumulated deficit	Total	Non-controlling Interest	Total
Balance at Dec. 31, 2019	$ 410	$ 1,500	$ 2	$ 48,051	$ (63,340)	$ (13,377)	$ 3,501	$ (9,876)
Changes during the period:
Issuance of ordinary shares, net	131			5,173		5,304		5,304
Issuance of shares within share based compensation	11			467		478		478
Conversion of financial liability to shares	20			702		722		722
Conversion of loans from controlling shareholder into shares	93			4,907		5,000		5,000
Comprehensive loss for the period:
Loss for the period					(4,900)	(4,900)	(81)	(4,981)
Other comprehensive income
Total comprehensive loss for the period					(4,900)	(4,900)	(81)	(4,981)
Balance at Jun. 30, 2020	665	1,500	2	59,300	(68,240)	(6,773)	3,420	(3,353)
Balance at Dec. 31, 2020	819	1,500	2	67,257	(75,876)	(6,298)	3,349	(2,949)	[1]
Changes during the period:
Issuance of ordinary shares, net	270			13,144		13,414		13,414
Issuance of shares within share based compensation	95			(98)		(3)		(3)
Conversion of financial liability to shares	28			931		959		959
Comprehensive loss for the period:
Loss for the period					(4,694)	(4,694)	(77)	(4,771)
Other comprehensive income
Total comprehensive loss for the period					(4,694)	(4,694)	(77)	(4,771)
Balance at Jun. 30, 2021	$ 1,212	$ 1,500	$ 2	$ 81,234	$ (80,570)	$ 3,378	$ 3,272	$ 6,650
[1]	The December 31, 2020 balances were derived from the Company’s audited annual financial statements.

Unaudited Interim Condensed C_4

Unaudited Interim Condensed Consolidated Statements of Cash Flow - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flow from operating activities:
Net loss for the period	$ (4,771)	$ (4,981)
Adjustments:
Depreciation and amortization	691	1,031
Share based compensation	(3)	478
Change in fair value of derivative liabilities – warrants	(423)	(439)
Capital loss from sale of fixed assets	16
Accrued interest of long-term loans	81	52
Changes in deferred tax		(9)
Change in fair value of convertible debenture	794
Total adjustments	1,156	1,113
Changes in assets and liabilities:
Decrease (Increase) in trade receivable	45	(28)
Decrease in other accounts receivable	493	39
Decrease in inventories	44	254
Increase (decrease) in trade payables	196	(955)	[1]
Increase (decrease) in other accounts payable	1,650	1,799	[1]
Accrued interest on loan from controlling shareholder	23	260
Change in restricted deposit	1	6
Total assets and liabilities	2,452	1,375
Net cash used in operating activities	(1,163)	(2,493)
Cash flow from investing activities
Purchase of property, plant and equipment		(207)
Proceeds from sale of fixed assets	66
Deposit in restricted deposit		82
Net cash used in / provided by investing activities	66	(125)
Cash flow from financing activities
Issuance of ordinary shares, net	13,414	5,789
Loan received from controlling shareholder	347	121
Receipts of long-term loans		873
Principal paid on lease liabilities	(189)	(259)
Repayment of long -term loans	(123)	(194)
Short-term bank credit		(93)
Repayment of financial liability		(3,001)
Receipt (repayment (convertible debenture	343	(75)
Receipt of derivative liabilities – warrants	407
Net cash provided by financing activities	14,199	3,161
Increase (decrease) in cash and cash equivalents	13,102	543
Cash and cash equivalents at beginning of the period	278
Effects of exchange rate changes on cash and cash equivalents			[1]
Cash and cash equivalents at the end of the period	13,380	543
Conversion of convertible debenture into shares		722
Conversion of convertible debenture into financial liability		682
Conversion of loans into shares	959
Conversion of loan from controlling shareholder into shares		5,000
Non-cash issuance expenses in warrants		$ 485
[1]	Reclassification

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS: Overview G Medical Innovations Holdings Ltd. (“G Medical” and together with its subsidiaries, the “Company”) was incorporated in October 2014 under the Cayman Island law. G Medical’s registered address is P.O. Box 10008, Willow House, Cricket Square, Grand Cayman, KY1-1001, Cayman Islands. In May 2017, the Company was admitted to the official list on the Australian Stock Exchange (“ASX”) under the symbol GMV. In October 2020, the Company voluntarily delisted itself from the Official List on the Australian Stock Exchange (“ASX”). In June 2021, the Company succeeded to close its initial public offering of 3,000,000 units, each unit consisting of one ordinary share and one warrant to purchase one ordinary share of the Company for gross proceeds of approximately $15,000 before deducting underwriting discounts and commissions and other offering-related expenses in the amount of $2,150. Only the costs attributable to the issuance of new shares that were deducted from equity. Listing costs were expensed. The ordinary shares and warrants of the Company began trading on the Nasdaq Capital Market on June 25, 2021, under the symbols “GMVD” and “GMVDW,” respectively. The Company is ushering in a new era of healthcare and wellness by utilizing its patent-pending wireless technologies, and proprietary information technology and service platforms operating by two segments (see note 7), to empower a new generation of consumers, patients and providers to improve quality of life. The Company develops the next generation of mobile technologies that will empower consumers and providers to better monitor, manage, and improve clinical and personal health outcomes. The Company offers a suite of both consumer and clinical grade products and platforms which are positioned to reduce inefficiencies in healthcare delivery, improve access, reduce costs, increase quality of care, and make healthcare more personalized and precise.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Basis of preparation These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standards (the “IAS”) 34 Interim Financial Reporting. They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the 2020 annual consolidated financial statements. The Company has applied the same accounting policies and methods of computation in its interim consolidated financial statements as in its 2020 annual consolidated financial statements. Impact of accounting standards to be applied in future periods There are a number of standards and interpretations which have been issued by the International Accounting Standards Board that are effective for periods beginning subsequent to December 31, 2021 (the date on which the Company’s next annual financial statements will be prepared up to) that the Company has decided not to adopt early. The Company does not believe these standards and interpretations will have a material impact on the financial statements once adopted.

Significant Events and Transact

Significant Events and Transactions in the Period	6 Months Ended
	Jun. 30, 2021
Significant Events And Transactions In The Period [Abstract]
SIGNIFICANT EVENTS AND TRANSACTIONS IN THE PERIOD	NOTE 3 – SIGNIFICANT EVENTS AND TRANSACTIONS IN THE PERIOD: A. CLA Transaction (Alpha Capital): On December 21, 2020, the Company entered into a transaction (the “Initial Alpha CLA Transaction”), whereby the Company entered into a securities purchase agreement with Alpha Capital Anstalt (“Alpha”), pursuant to which the Company obtained a convertible loan in the aggregate amount of $350 against issuance of a convertible debenture and warrants to purchase 79,666 ordinary shares. The Initial Alpha CLA Transaction debenture has a six-month term from issuance and bear interest at 10% per annum. The Initial Alpha CLA Transaction debenture is convertible into the ordinary shares at a conversion price equal to 80% of the public offering price per share in the Company’s initial public offering on Nasdaq in June 2021. Initial Alpha CLA Transaction warrants have an exercise price per share equal to the per share price of the Company’s ordinary shares in the Nasdaq IPO in June, and have a five-year term. In addition, Alpha was also provided a right to purchase an additional $150 of a convertible debenture and warrants on the same terms as in the Initial Alpha CLA transaction (the “Subsequent Alpha CLA Transaction”). On February 17, 2021 Alpha exercised the foregoing right to invest $150 against issuance of additional convertible debentures and warrants to purchase 34,142 ordinary shares (the “Second CLA Transaction”). As of June 30, 2021, these convertible debentures amounted to $588, and the warrants amounted to $136. As of June 21, 2021, the debentures issued pursuant to the Initial Alpha CLA Transaction matured, and as of August 21, 2021, the debentures issued pursuant to the Subsequent Alpha CLA Transaction matured. To date, the Company has not repaid the foregoing debentures, and is discussing with Alpha the terms of repayment, and/or conversion. In case of cash consideration, the Company will pay Alpha $350 plus interest of 10% per annum in respect of the Initial Alpha CLA Transaction and $150 plus interest of 10% per annum in respect of the Subsequent Alpha CLA Transaction. The convertible debentures, as well as the warrants and the right to purchase additional convertible debentures were classified as a derivative financial liability (see measurement method in note 6). The fair value of the Initial CLA Transaction is based on the assumption of converting into Units (shares and warrants). B. Change in authorized share capital and reverse stock split: On March 17, 2021, the Company gave public notice of an extraordinary general shareholders meeting to approve a reverse stock split, such that: All ordinary shares (issued and unissued) be consolidated on the basis that every five ordinary shares of par value $0.018 will be consolidated into one ordinary share of par value $0.09, such that the authorized ordinary share capital of the Company following such consolidation is $180,000 divided into 2,000,000,000 ordinary shares of a par value of $0.09 each. The reverse stock split and the amendments to the Company’s authorized share capital entered into effect on March 25, 2021 (which is the date of the above referenced extraordinary general shareholders meeting). All shares, per share information and notes thereto have been retroactively adjusted for the reverse stock split as if such split occurred on the first day of the first period presented. C. CLA Transactions (Jonathan B. Rubini): On April 7, 2021, the Company entered into a transaction, whereby the Company entered into a securities purchase agreement, with Jonathan B. Rubini, pursuant to which the Company obtained a convertible loan in an aggregate amount of $600, against issuance of a convertible debenture, and warrants to purchase 136,571 ordinary shares at the same terms as the Initial Alpha CLA Transactions. As of June 30, 2021, this convertible debenture amounted to $743, and the warrants amounted to $169. The foregoing convertible debenture, as well as the warrants and the right to purchase additional convertible debentures were classified as a derivative financial liability (see measurement method in note 6). D. World event - Coronavirus (COVID 19): The global pandemic resulting from the disease known as COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions and may adversely impact our business. Although the Company did see an increase in revenue for the six months ended June 30, 2021 due to the to the impact of lifting of social restrictions related to COVID-19 pandemic, which led to patients returning to their doctors for medical tests. The Company cannot predict the duration or magnitude of the pandemic or the full impact that it may have on the Company’s operations and workforce, including the Company’s research and clinical trials and its ability to raise capital, which in turn could have an adverse impact on the Company’s business, financial condition and results of operation. In April 2020, under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) in the United States, the Company’s U.S. subsidiary signed an agreement with the U.S. Small Business Administration (“SBA”) to receive a loan according to the Paycheck Protection Program (“PPP”) in the amount of approximately $900 from Bank of America. According to the terms of the PPP loan, the payments will be deferred for six months from the funding date and no collateral or personal guarantees are required. The PPP loan has a maturity of two years and bears an interest rate of 1%. A borrower can apply for forgiveness once all loan proceeds for which the borrower is requesting forgiveness have been used. The Company applied for forgiveness for the PPP Loan. The PPP loan was accounted for as a deduction from wage expenses in 2020 and not as a loan liability since all conditions for waiver were met as of December 31, 2020. On April 3, 2021, the Company received approval for full forgiveness from the SBA and the loan was fully paid from SBA to Bank of America. E. Nasdaq IPO: On June 29, 2021, the Company closed its initial public offering of 3,000,000 units. (See Note 1 and Note 5).

Related Parties and Shareholder

Related Parties and Shareholders	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTIES AND SHAREHOLDERS	NOTE 4 - RELATED PARTIES AND SHAREHOLDERS: During the six-month period ended June 30, 2021, the Company issued to the Company’s CEO, Dr. Yacov Geva, In addition to his ordinary salary, 1,055,555 ordinary shares and paid a bonus in the amount of $240 in consideration of his service to the Company and subject to the consummation of the June 2021 initial public offering.

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
SHAREHOLDERS' EQUITY (DEFICIT)	NOTE 5 - SHAREHOLDERS’ EQUITY (DEFICIT): The ordinary shares in the Company confer upon their holders the right to receive notice to participate and vote in general meetings of the Company, and the right to receive dividends, if and when declared. Number of shares June 30, 2021 December 31, 2020 Unaudited Authorized Issued and outstanding Authorized Issued and outstanding Ordinary shares of $0.09 par value 2,000,000,000 13,464,746 2,000,000,000 * 9,103,924 * Warrants** 3,450,000 3,450,000 - - (*) After giving effect to the reverse stock split of 18:1 on October 29, 2020 and reverse stock split of 5:1 on March 25, 2021 (see below). (**) the Warrants will be exercisable at a price equal to $6.25 per share and for a period of five years, starting from June 2021. On October 29, 2020, the Company shareholders approved, a one-for-18 consolidation (hereinafter referred to as the reverse stock split of 18:1) of the Company’s ordinary shares pursuant to which holders of the ordinary shares received one ordinary share for every 18 ordinary share held. In addition, on March 25, 2021, the Company’s shareholders approved, a one-for-5 consolidation (hereinafter referred to as a reverse stock split of 5:1) of the Company’s ordinary shares pursuant to which holders of the Company’s ordinary shares received one ordinary share for every 5 ordinary share held. On June 29, 2021, the Company closed its initial public offering of 3,000,000 units. Each unit consisted of one Ordinary Shares and one warrant to purchase one ordinary share at a price to the public of $5 per unit. The gross proceeds to the Company from the initial public offering were $15,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The total issue expenses were in the amount of $2,150 whereas only the costs attributable to the offer of new shares are deducted from equity. The Company also granted an option to the underwriter to purchase up to 450,000 additional ordinary shares and/or warrants at the public offering price less the underwriting discount. The underwriters exercise the option to purchase 450,000 warrants. The Warrant were immediately exercisable on the date of issuance at an exercise price of $6.25 per ordinary share (125% of the public offering price per Unit) and will expire four years from the date of issuance. In addition, and upon the consummation of the Company’s initial public offering, the Company issued 305,267 ordinary shares upon the conversion of approximately $1,200 of outstanding debt (part of the Company short- and long-term loans) associated with the Company’s acquisition of CardioStaff in November 2017, which was calculated based upon 80% of the public offering price of $5 per unit in the initial public offering. The Company issued 1,055,555 ordinary shares at par value of $0.09 to the Company’s CEO, Dr. Yacov Geva, as part of a bonus for completing the Company’s initial public offering.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	NOTE 6 The following table sets out the Company’s liabilities that are measured at fair value in the financial statements: Fair value measurements using input type June 30, 2021 (Unaudited) Level 1 Level 2 Level 3 Total Derivative liability - warrants (343 ) (343 ) Convertible debentures (1,331 ) (1,331 ) Fair value measurements using input type December 31, 2020 Level 1 Level 2 Level 3 Total Derivative liability - warrants - - (359 ) (359 ) Convertible debenture - - (194 ) (194 ) As of June 30, 2021, the fair value measurement of the warrant’s securities in the table above, was estimated using the Black Scholes model, based on a variety of significant unobservable inputs and thus represent a level 3 measurement within the fair value hierarchy. The measurement of the convertible debentures in the table above, was estimated as follows: 1. Alpha Capital convertible debentures were estimated under the assumption of converting to shares according to the fair value of the shares. 2. Jonathan B. Rubini convertible debenture which conversion date is October 2021 were estimated using a Monte Carlo simulation analysis, based on a variety of significant unobservable inputs a thus represent a level 3 measurement within the fair value hierarchy. The key inputs that were used in the convertible debenture and warrants valuation were: risk-free interest rate – 0.88%, expected volatility - 50 % and AUD/USD exchange rate - 0.75 As of December 31, 2020, the fair value measurement of the convertible debenture and the warrant’s securities in the table above, was estimated using a Monte Carlo simulation analysis, based on a variety of significant unobservable inputs a thus represent a level 3 measurement within the fair value hierarchy. The key inputs that were used in warrants and the convertible securities were: the risk-free interest rate- 0.12%, the expected volatility-100% and the AUD/USD exchange rate -0.7724. The following tables describes the change in the Company’s liabilities that are measured at level 3 in the financial statements: Derivative Derivative liability - warrants as of December 31, 2020 (359 ) Issuance of financial instruments (407 ) Change in fair value 423 Derivative liability - warrants as of June 30, 2021 (343 ) Convertible Convertible debenture as of December 31, 2020 (194 ) issuance of convertible debenture (343 ) Gain due to change in fair value of convertible debenture (794 ) Convertible debenture as of June 30, 2021 (1,331 )

Revenue

Revenue	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
REVENUE	NOTE 7 - REVENUE: For the six months ended June 30, 2020 and June 30, 2021 total revenues consist primarily of monitoring patient services (approximately 98.6% and 98.3% respectively) which were generated in the U.S.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 8 - SEGMENT REPORTING: The Company accounts for its segment information in accordance with IFRS 8 “Segment Reporting” which establishes annual and interim reporting standards for operating segments of a Company based on the Company’s internal accounting methods. Operating segments are based upon its internal organization structure, the manner in which our operations are managed and the availability of separate financial information. The Company has two operating segments: Products segment and Patient services segment. Products: Development, manufacture and marketing of trans-telephonic and wireless diagnostic equipment for the medical industry and consumer market. Mobile medical device platform designed for self-testing of vital signs for the consumer market. Patient Services: Cardiac monitoring services of MCT, Event, Holter and Extended Holter. Summarized financial information by segment, based on the Company’s internal financial reporting system utilized by the Company’s chief operating decision makers, follows: For the six-months period ended June 30, 2021: Products: Patient Total: Unaudited Revenues from external customers 50 2,875 2,925 Segment loss 1,528 883 2,411 Unallocated general and administrative expenses 1,862 Finance expenses, net 503 Loss before taxes on income 4,776 For the six-months period ended June 30, 2020: Products: Patient Total: Unaudited Revenues from external customers 29 1,981 2,010 Segment loss 1,739 1,828 3,567 Unallocated general and administrative expenses 1,067 Finance expenses, net 356 Loss before taxes on income 4,990

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 - SUBSEQUENT EVENTS: Options granted to directors and management On September 5, 2021, the Board of the Company approved to issue Options to the directors and to the management a total of 900,000 Options that will become vested and exercisable over a period of three years, with exercise price per Option of US$ 3.27.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of preparation	Basis of preparation These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standards (the “IAS”) 34 Interim Financial Reporting. They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the 2020 annual consolidated financial statements. The Company has applied the same accounting policies and methods of computation in its interim consolidated financial statements as in its 2020 annual consolidated financial statements.
Impact of accounting standards to be applied in future periods	Impact of accounting standards to be applied in future periods There are a number of standards and interpretations which have been issued by the International Accounting Standards Board that are effective for periods beginning subsequent to December 31, 2021 (the date on which the Company’s next annual financial statements will be prepared up to) that the Company has decided not to adopt early. The Company does not believe these standards and interpretations will have a material impact on the financial statements once adopted.

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings	Number of shares June 30, 2021 December 31, 2020 Unaudited Authorized Issued and outstanding Authorized Issued and outstanding Ordinary shares of $0.09 par value 2,000,000,000 13,464,746 2,000,000,000 * 9,103,924 * Warrants** 3,450,000 3,450,000 - -

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of liabilities that are measured at fair value in the financial statements	Fair value measurements using input type June 30, 2021 (Unaudited) Level 1 Level 2 Level 3 Total Derivative liability - warrants (343 ) (343 ) Convertible debentures (1,331 ) (1,331 ) Fair value measurements using input type December 31, 2020 Level 1 Level 2 Level 3 Total Derivative liability - warrants - - (359 ) (359 ) Convertible debenture - - (194 ) (194 )
Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements	Derivative Derivative liability - warrants as of December 31, 2020 (359 ) Issuance of financial instruments (407 ) Change in fair value 423 Derivative liability - warrants as of June 30, 2021 (343 )
Schedule of liabilities that are measured at level 3 in the convertible debenture financial statements	Convertible Convertible debenture as of December 31, 2020 (194 ) issuance of convertible debenture (343 ) Gain due to change in fair value of convertible debenture (794 ) Convertible debenture as of June 30, 2021 (1,331 )

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Schedule of products and patient services	Products: Patient Total: Unaudited Revenues from external customers 50 2,875 2,925 Segment loss 1,528 883 2,411 Unallocated general and administrative expenses 1,862 Finance expenses, net 503 Loss before taxes on income 4,776 Products: Patient Total: Unaudited Revenues from external customers 29 1,981 2,010 Segment loss 1,739 1,828 3,567 Unallocated general and administrative expenses 1,067 Finance expenses, net 356 Loss before taxes on income 4,990

Description of Business (Detail

Description of Business (Details)	1 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Initial public offering description	In June 2021, the Company succeeded to close its initial public offering of 3,000,000 units, each unit consisting of one ordinary share and one warrant to purchase one ordinary share of the Company for gross proceeds of approximately $15,000 before deducting underwriting discounts and commissions and other offering-related expenses in the amount of $2,150.

Significant Events and Transa_2

Significant Events and Transactions in the Period (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 07, 2021	Jun. 29, 2021	Feb. 17, 2021	Dec. 21, 2020	Jun. 30, 2021	Mar. 17, 2021	Apr. 30, 2020
Significant Events and Transactions in the Period (Details) [Line Items]
Convertible loan amount				$ 350
Ordinary shares purchase (in Shares)			34,142	79,666
Bear interest					10.00%		1.00%
Conversion price, percentage					80.00%
Convertible debenture			$ 150		$ 150
Warrants amount					$ 136
Ordinary share par value (in Dollars per share)					$ 90	$ 0.09
Share capital value						$ 180,000
Ordinary shares authorized (in Shares)						2,000,000,000
Initial public offering (in Shares)		3,000,000,000
Initial Alpha CLA [Member]
Significant Events and Transactions in the Period (Details) [Line Items]
Convertible debenture					$ 588
Cash consideration					$ 350
Interest rate					10.00%
Subsequent alpha CLA [Member]
Significant Events and Transactions in the Period (Details) [Line Items]
Cash consideration					$ 150
Interest rate					10.00%
CLA [Member]
Significant Events and Transactions in the Period (Details) [Line Items]
Convertible loan amount	$ 600
Ordinary shares purchase (in Shares)	136,571
Convertible debenture					$ 743
Warrants amount					$ 169
Paycheck Protection Program [Member]
Significant Events and Transactions in the Period (Details) [Line Items]
Loan received							$ 900
Five ordinary shares [Member]
Significant Events and Transactions in the Period (Details) [Line Items]
Ordinary share par value (in Dollars per share)						$ 0.018
One ordinary shares [Member]
Significant Events and Transactions in the Period (Details) [Line Items]
Ordinary share par value (in Dollars per share)						$ 0.09
IPO [Member]
Significant Events and Transactions in the Period (Details) [Line Items]
Initial public offering (in Shares)		3,000,000

Related Parties and Sharehold_2

Related Parties and Shareholders (Details) - Dr. Yacov Geva [Member] $ in Thousands	Jun. 30, 2021USD ($)shares
Related Parties and Shareholders (Details) [Line Items]
Ordinary shares | shares	1,055,555
Paid bonus amount | $	$ 240

Shareholders' Equity (Deficit_2

Shareholders' Equity (Deficit) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Jun. 29, 2021	Nov. 30, 2017	Jun. 30, 2021	Mar. 17, 2021
Shareholders' Equity (Deficit) (Details) [Line Items]
Exercisable price per share	$ 6,250		$ 6,250
Number of shares	3,000,000,000
Price per share	$ 5,000	$ 5,000
Additional ordinary shares purchase	450,000,000
Exercise option to purchase warrants	450,000,000
Shares issued		305,267,000	1,055,555,000
Outstanding debt		$ 1,200
Par value			$ 90	$ 0.09
Warrant [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Public offering price per unit percentage	125.00%
Common Stock [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Public offering price per unit percentage		80.00%
Initial Public Offering [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Number of shares	3,000,000
Initial public offering, description	The gross proceeds to the Company from the initial public offering were $15,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The total issue expenses were in the amount of $2,150 whereas only the costs attributable to the offer of new shares are deducted from equity.

Shareholders' Equity (Deficit_3

Shareholders' Equity (Deficit) (Details) - Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings - shares shares in Thousands		Jun. 30, 2021	Dec. 31, 2020
Common Stock [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings [Line Items]
Authorized, ordinary shares		2,000,000,000	2,000,000,000	[1]
Issued and outstanding, warrants		13,464,746	9,103,924	[1]
Warrant [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings [Line Items]
Authorized, ordinary shares	[2]	3,450,000
Issued and outstanding, warrants	[2]	3,450,000
[1]	After giving effect to the reverse stock split of 18:1 on October 29, 2020 and reverse stock split of 5:1 on March 25, 2021 (see below).
[2]	the Warrants will be exercisable at a price equal to $6.25 per share and for a period of five years, starting from June 2021.

Fair Value Measurement (Details

Fair Value Measurement (Details)	1 Months Ended	6 Months Ended
	Dec. 31, 2020	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Risk-free interest rate	0.12%	0.88%
Expected volatility		50.00%
Exchange rate	0.7724	0.75
Expected volatility ,description	the expected volatility-100% and the AUD/USD exchange rate -0.7724.

Fair Value Measurement (Detai_2

Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements [Line Items]
Derivative liability - warrants	$ (343)	$ (359)
Convertible debenture	(1,331)	(194)
Level 3 [Member]
Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements [Line Items]
Derivative liability - warrants	(343)	(359)
Convertible debenture	$ (1,331)	(194)
Level 1 [Member]
Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements [Line Items]
Derivative liability - warrants
Convertible debenture
Level 2 [Member]
Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements [Line Items]
Derivative liability - warrants
Convertible debenture

Fair Value Measurement (Detai_3

Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements - Derivative liability warrants [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements [Line Items]
Derivative liability - warrants as of December 31, 2020	$ (359)
Issuance of financial instruments	(407)
Change in fair value	423
Derivative liability - warrants as of June 30, 2021	$ (343)

Fair Value Measurement (Detai_4

Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the convertible debenture financial statements - Convertible debenture [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Short-term Debt [Line Items]
Convertible debenture as of December 31, 2020	$ (194)
issuance of convertible debenture	(343)
Gain due to change in fair value of convertible debenture	(794)
Convertible debenture as of June 30, 2021	$ (1,331)

Revenue (Details)

Revenue (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Patient services	98.60%	98.30%

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of products and patient services - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting Information [Line Items]
Revenues from external customers	$ 2,925	$ 2,010
Segment loss	2,411	3,567
Unallocated general and administrative expenses	1,862	1,067
Finance expenses, net	503	356
Loss before taxes on income	4,776	4,990
Product [Member]
Segment Reporting Information [Line Items]
Revenues from external customers	50	29
Segment loss	1,528	1,739
Patient Services [Member]
Segment Reporting Information [Line Items]
Revenues from external customers	2,875	1,981
Segment loss	$ 883	$ 1,828

Subsequent Events (Details)

Subsequent Events (Details) - Forecast [Member]	Sep. 05, 2021$ / sharesshares
Subsequent Events (Details) [Line Items]
Issued options shares | shares	900,000
Vested period	3 years
Exercise price per share | $ / shares	$ 3.27